IgE-based immunotherapy of cancer: Challenges and chances

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 2, 2014, Pages 137-149

  Singer, J ^a   Jensen Jarolim, E ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AllergoOncology; comparative oncology; IgE; passive immunotherapy

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; CETUXIMAB; FC RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IPILIMUMAB; OFATUMUMAB; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BASOPHIL; CANCER IMMUNOTHERAPY; CELL DEATH; CELL KILLING; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNOCOMPETENT CELL; MAST CELL; NEOPLASM; NONHUMAN; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ALLERGOONCOLOGY; COMPARATIVE ONCOLOGY; IGE; PASSIVE IMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; NEOPLASMS;

EID: 84893673969     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12276     Document Type: Review

References (192)

1. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008; 63: 1255-1266.
2. Jensen-Jarolim E, Pawelec G,. The nascent field of AllergoOncology. Cancer Immunol Immunother 2012; 61: 1355-1357.
3. Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE,. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005; 162: 212-221. (Pubitemid 41373525)
4. Turner MC, Chen Y, Krewski D, Ghadirian P,. An overview of the association between allergy and cancer. Int J Cancer 2006; 118: 3124-3132.
5. Turner MC,. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother 2012; 61: 1493-1510.
6. Schlehofer B, Siegmund B, Linseisen J, Schuz J, Rohrmann S, Becker S, et al. Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy 2011; 66: 1434-1441.
7. Plymoth A, Viviani S, Hainaut P,. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett 2009; 286: 15-21.
8. Bilusic M, Madan RA,. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther 2012; 19: e172-e181.
9. Carballido E, Fishman M,. Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011; 13: 112-119.
10. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
11. Boyiadzis M, Foon KA,. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008; 8: 1151-1158.
12. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100: 1265-1273. (Pubitemid 34864281)
13. Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR,. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 2011; 60: 985-997.
14. Comen EA, Fornier MN,. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. Clin Breast Cancer 2010; 10 (Suppl 2): S7-S19.
15. Javle M, Hsueh CT,. Recent advances in gastrointestinal oncology-updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010; 3: 11.
16. Li Y, Zhu Z,. Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther 2007; 7: 319-330. (Pubitemid 46383475)
17. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26: 5950-5956.
18. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013; 119: 3687-3695.
19. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013; 18: 726-732.
20. Rughani MG, Gupta A, Middleton MR,. New treatment approaches in melanoma: current research and clinical prospects. Ther Adv Med Oncol 2013; 5: 73-80.
21. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767-1775.
22. Weber J,. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-439.
23. Robert C, Soria JC, Eggermont AM,. Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013; 49: 2968-2971.
24. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
25. Morris JC, Waldmann TA,. Antibody-based therapy of leukaemia. Expert Rev Mol Med 2009; 11: e29.
26. Pirrotta MT, Bernardeschi P, Fiorentini G,. Targeted-therapy in advanced renal cell carcinoma. Curr Med Chem 2011; 18: 1651-1657.
27. Lo HW, Hung MC,. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006; 94: 184-188.
28. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. (Pubitemid 19147683)
29. Scott AM, Allison JP, Wolchok JD,. Monoclonal antibodies in cancer therapy. Cancer Immun 2012; 12: 14.
30. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM,. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-311. (Pubitemid 40544648)
31. Ferrara N, Hillan KJ, Gerber HP, Novotny W,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. (Pubitemid 38618122)
32. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F,. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 1-9.
33. Ferris RL, Jaffee EM, Ferrone S,. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 4390-4399.
34. Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009; 58: 915-930.
35. Neuberger MS, Rajewsky K,. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981; 11: 1012-1016. (Pubitemid 12212156)
36. Bindon CI, Hale G, Bruggemann M, Waldmann H,. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168: 127-142.
37. Wang SY, Weiner G,. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008; 8: 759-768. (Pubitemid 351860205)
38. Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013; 5: 185ra163.
39. Reichert JM, Valge-Archer VE,. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-356. (Pubitemid 46696550)
40. Bournazos S, Woof JM, Hart SP, Dransfield I,. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009; 157: 244-254.
41. Iannello A, Ahmad A,. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487-499. (Pubitemid 43096997)
42. Nimmerjahn F, Ravetch JV,. Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28. (Pubitemid 43077197)
43. Masui H, Moroyama T, Mendelsohn J,. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 1986; 46: 5592-5598. (Pubitemid 17177952)
44. Schroeder HW Jr, Cavacini L,. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125 (Suppl 2): S41-S52.
45. Mix E, Goertsches R, Zett UK,. Immunoglobulins-basic considerations. J Neurol 2006; 253 (Suppl 5): V9-V17.
46. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-3725.
47. Aalberse RC, Schuurman J,. IgG4 breaking the rules. Immunology 2002; 105: 9-19. (Pubitemid 34128035)
48. Aalberse RC, Stapel SO, Schuurman J, Rispens T,. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-477.
49. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M,. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008; 63: 1455-1463.
50. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 123: 1457-1474.
51. Huang J, Shibaguchi H, Zhao J, Luo N, Kuroki M, Kinugasa T, et al. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity. Anticancer Res 2006; 26: 1057-1063.
52. Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC,. Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases. J Virol 2007; 81: 1313-1318. (Pubitemid 46167852)
53. Clynes RA, Towers TL, Presta LG, Ravetch JV,. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446. (Pubitemid 30208162)
54. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M,. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114. (Pubitemid 27314146)
55. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
56. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758. (Pubitemid 34525533)
57. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
58. Robinson JI, Carr IM, Cooper DL, Rashid LH, Martin SG, Emery P, et al. Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. Hum Mutat 2012; 33: 741-749.
59. Willcocks LC, Lyons PA, Clatworthy MR, Robinson JI, Yang W, Newland SA, et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008; 205: 1573-1582. (Pubitemid 351962021)
60. Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, et al. Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat 2009; 30: E640-E650.
61. Molokhia M, Fanciulli M, Petretto E, Patrick AL, McKeigue P, Roberts AL, et al. FCGR3B copy number variation is associated with systemic lupus erythematosus risk in Afro-Caribbeans. Rheumatology (Oxford) 2011; 50: 1206-1210.
62. Mueller M, Barros P, Witherden AS, Roberts AL, Zhang Z, Schaschl H, et al. Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus. Am J Hum Genet 2013; 92: 28-40.
63. Nossent JC, Rischmueller M, Lester S,. Low copy number of the Fc-gamma receptor 3B gene FCGR3B is a risk factor for primary Sjogren's syndrome. J Rheumatol 2012; 39: 2142-2147.
64. Graf SW, Lester S, Nossent JC, Hill CL, Proudman SM, Lee A, et al. Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. Arthritis Res Ther 2012; 14: R28.
65. Zhou XJ, Lv JC, Bu DF, Yu L, Yang YR, Zhao J, et al. Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. Int Immunol 2010; 22: 45-51.
66. McKinney C, Merriman TR,. Meta-analysis confirms a role for deletion in FCGR3B in autoimmune phenotypes. Hum Mol Genet 2012; 21: 2370-2376.
67. Olsson LM, Holmdahl R,. Copy number variation in autoimmunity-importance hidden in complexity? Eur J Immunol 2012; 42: 1969-1976.
68. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007; 67: 8882-8890. (Pubitemid 47437465)
69. Ashraf SQ, Umana P, Mossner E, Ntouroupi T, Brunker P, Schmidt C, et al. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009; 101: 1758-1768.
70. Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, et al. Preclinical study of a glycoengineered anti-human Cd20 antibody in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013; 54: 3657-3665.
71. Ogura M, Tobinai K, Hatake K, Uchida T, Suzuki T, Kobayashi Y, et al. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2013; 104: 105-110.
72. Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119: 5118-5125.
73. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29: 3783-3790.
74. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose. N Engl J Med 2008; 358: 1109-1117. (Pubitemid 351398485)
75. Shulman M, Wilde CD, Kohler G,. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276: 269-270. (Pubitemid 9053903)
76. Galili U,. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 2005; 83: 674-686. (Pubitemid 43083100)
77. Koike C, Uddin M, Wildman DE, Gray EA, Trucco M, Starzl TE, et al. Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci USA 2007; 104: 559-564. (Pubitemid 46123064)
78. Milland J, Sandrin MS,. ABO blood group and related antigens, natural antibodies and transplantation. Tissue Antigens 2006; 68: 459-466. (Pubitemid 44924119)
79. Galili U,. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology 2013; 140: 1-11.
80. Commins SP, Kelly LA, Ronmark E, James HR, Pochan SL, Peters EJ, et al. Galactose-alpha-1,3-galactose-specific IgE is associated with anaphylaxis but not asthma. Am J Respir Crit Care Med 2012; 185: 723-730.
81. Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2011; 127: 1286-1293.
82. Castells M, Sancho-Serra Mdel C, Simarro M,. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012; 61: 1575-1584.
83. Bluth MH,. IgE and chemotherapy. Cancer Immunol Immunother 2012; 61: 1585-1590.
84. Vollmers HP, Brandlein S,. Natural antibodies and cancer. N Biotechnol 2009; 25: 294-298.
85. Schwartz-Albiez R,. Naturally occurring antibodies directed against carbohydrate tumor antigens. Adv Exp Med Biol 2012; 750: 27-43.
86. Dobroff AS, Rodrigues EG, Juliano MA, Friaca DM, Nakayasu ES, Almeida IC, et al. Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells. Transl Oncol 2010; 3: 204-217.
87. Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E,. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 1978; 271: 67-69. (Pubitemid 8240067)
88. Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT,. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001; 40: 750-756.
89. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011; 3: 99ra85.
90. Harper J, Mao S, Strout P, Kamal A,. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. Methods Mol Biol 2013; 1045: 41-49.
91. Kracker S, Durandy A,. Insights into the B cell specific process of immunoglobulin class switch recombination. Immunol Lett 2011; 138: 97-103.
92. Shoreibah MG, Jackson CL, Price PW, Meagher R, Godwin AK, Cai Q, et al. Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas. Stem Cells Dev 2011; 20: 515-525.
93. Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, Livingston PO, et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 2011; 17: 1024-1032.
94. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 4574-4580. (Pubitemid 35429700)
95. Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 2011; 186: 3770-3778.
96. Monteiro RC,. Role of IgA and IgA fc receptors in inflammation. J Clin Immunol 2010; 30: 1-9.
97. Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007; 179: 2936-2943.
98. Lohse S, Peipp M, Beyer T, Valerius T, Dechant M,. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies. Arch Immunol Ther Exp (Warsz) 2010; 58: 303-312.
99. Otten MA, Rudolph E, Dechant M, Tuk CW, Reijmers RM, Beelen RH, et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol 2005; 174: 5472-5480. (Pubitemid 40593187)
100. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008; 153: 401-409.
101. Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, et al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 2008; 57: 247-263. (Pubitemid 350159926)
102. Turcanu V, Stephens AC, Chan SM, Rance F, Lack G,. IgE-mediated facilitated antigen presentation underlies higher immune responses in peanut allergy. Allergy 2010; 65: 1274-1281.
103. Riffo-Vasquez Y, Pitchford S, Spina D,. Murine models of inflammation: role of CD23. Allergy 2000; 55 (Suppl 61): 21-26. (Pubitemid 30430374)
104. Zuberi RI, Hsu DK, Kalayci O, Chen HY, Sheldon HK, Yu L, et al. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 2004; 165: 2045-2053. (Pubitemid 39578382)
105. Liu FT,. Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol 2005; 136: 385-400.
106. Fridman WH,. Fc receptors and immunoglobulin binding factors. FASEB J 1991; 5: 2684-2690. (Pubitemid 21905820)
107. Gould HJ, Sutton BJ,. IgE in allergy and asthma today. Nat Rev Immunol 2008; 8: 205-217. (Pubitemid 351323292)
108. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179: 2832-2843.
109. Spillner E, Plum M, Blank S, Miehe M, Singer J, Braren I,. Recombinant IgE antibody engineering to target EGFR. Cancer Immunol Immunother 2012; 61: 1565-1573.
110. Shamri R, Xenakis JJ, Spencer LA,. Eosinophils in innate immunity: an evolving story. Cell Tissue Res 2011; 343: 57-83.
111. Lantero S, Alessandri G, Spallarossa D, Scarso L, Rossi GA,. Stimulation of eosinophil IgE low-affinity receptor leads to increased adhesion molecule expression and cell migration. Eur Respir J 2000; 16: 940-946. (Pubitemid 32049383)
112. Pereira MC, Oliveira DT, Kowalski LP,. The role of eosinophils and eosinophil cationic protein in oral cancer: a review. Arch Oral Biol 2011; 56: 353-358.
113. Newton DL, Rybak SM,. Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth. J Natl Cancer Inst 1998; 90: 1787-1791. (Pubitemid 28559890)
114. Dricu A, Sergiu-Bogdan C, Brismar K, Biberfeld P, Andersson LC,. A synthetic peptide derived from the human eosinophil-derived neurotoxin induces apoptosis in Kaposi's sarcoma cells. Anticancer Res 2004; 24: 1427-1432. (Pubitemid 38954659)
115. Bheekha-Escura R, MacGlashan DW, Langdon JM, MacDonald SM,. Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14-3D10. Blood 2000; 96: 2191-2198.
116. Melo RC, Liu L, Xenakis JJ, Spencer LA,. Eosinophil-derived cytokines in health and disease: unraveling novel mechanisms of selective secretion. Allergy 2013; 68: 274-284.
117. Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, et al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 2010; 185: 7443-7451.
118. Roth N, Stadler S, Lemann M, Hosli S, Simon HU, Simon D,. Distinct eosinophil cytokine expression patterns in skin diseases-the possible existence of functionally different eosinophil subpopulations. Allergy 2011; 66: 1477-1486.
119. Blanchard C, Rothenberg ME,. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121.
120. Walsh MT, Connell K, Sheahan AM, Gleich GJ, Costello RW,. Eosinophil peroxidase signals via HER2 to induce cell proliferation. Am J Respir Cell Mol Biol 2011; 45: 946-952.
121. Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT,. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002; 41: 152-157. (Pubitemid 34985188)
122. Lotfi R, Lee JJ, Lotze MT,. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 2007; 30: 16-28. (Pubitemid 46052200)
123. Lowe D, Jorizzo J, Hutt MS,. Tumour-associated eosinophilia: a review. J Clin Pathol 1981; 34: 1343-1348. (Pubitemid 12168683)
124. Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M,. Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother 2012; 61: 1527-1534.
125. Tadbir AA, Ashraf MJ, Sardari Y,. Prognostic significance of stromal eosinophilic infiltration in oral squamous cell carcinoma. J Craniofac Surg 2009; 20: 287-289.
126. Horiuchi K, Mishima K, Ohsawa M, Sugimura M, Aozasa K,. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J Surg Oncol 1993; 53: 92-96. (Pubitemid 23164594)
127. Horie N, Shimoyama T, Kaneko T, Ide F,. Multiple oral squamous cell carcinomas with blood and tissue eosinophilia. J Oral Maxillofac Surg 2007; 65: 1648-1650. (Pubitemid 47081288)
128. Martinelli-Klay CP, Mendis BR, Lombardi T,. Eosinophils and oral squamous cell carcinoma: a short review. J Oncol 2009; 2009: 310132.
129. Theoharides TC, Conti P,. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241. (Pubitemid 38501669)
130. Beaven MA,. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol 2009; 39: 11-25.
131. Descotes J, Choquet-Kastylevsky G,. Gell and Coombs's classification: is it still valid? Toxicology 2001; 158: 43-49. (Pubitemid 32119495)
132. Galli SJ, Tsai M,. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010; 40: 1843-1851.
133. Walker ME, Hatfield JK, Brown MA,. New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action? Biochim Biophys Acta 2012; 1822: 57-65.
134. Nechushtan H,. The complexity of the complicity of mast cells in cancer. Int J Biochem Cell Biol 2010; 42: 551-554.
135. Kneilling M, Rocken M,. Mast cells: novel clinical perspectives from recent insights. Exp Dermatol 2009; 18: 488-496.
136. Bara I, Ozier A, Tunon de Lara JM, Marthan R, Berger P,. Pathophysiology of bronchial smooth muscle remodelling in asthma. Eur Respir J 2010; 36: 1174-1184.
137. Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart FX, et al. Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 2002; 32: 237-246. (Pubitemid 34429602)
138. Ribatti D, Crivellato E,. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta 2012; 1822: 2-8.
139. Dawicki W, Marshall JS,. New and emerging roles for mast cells in host defence. Curr Opin Immunol 2007; 19: 31-38. (Pubitemid 46073696)
140. Siebenhaar F, Syska W, Weller K, Magerl M, Zuberbier T, Metz M, et al. Control of Pseudomonas aeruginosa skin infections in mice is mast cell-dependent. Am J Pathol 2007; 170: 1910-1916. (Pubitemid 47339265)
141. Crivellato E, Beltrami C, Mallardi F, Ribatti D,. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol 2003; 123: 19-21. (Pubitemid 37222753)
142. Dalton DK, Noelle RJ,. The roles of mast cells in anticancer immunity. Cancer Immunol Immunother 2012; 61: 1511-1520.
143. Aromando RF, Perez MA, Heber EM, Trivillin VA, Tomasi VH, Schwint AE, et al. Potential role of mast cells in hamster cheek pouch carcinogenesis. Oral Oncol 2008; 44: 1080-1087.
144. Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, et al. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci 2005; 98: 450-458. (Pubitemid 41297020)
145. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-1397. (Pubitemid 29270244)
146. de Souza DA Jr, Toso VD, Campos MR, Lara VS, Oliver C, Jamur MC,. Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression. PLoS ONE 2012; 7: e40790.
147. Siracusa MC, Comeau MR, Artis D,. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Ann N Y Acad Sci 2011; 1217: 166-177.
148. Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H,. Basophil recruitment and activation in inflammatory skin diseases. Allergy 2011; 66: 1107-1113.
149. Voehringer D,. Basophils in allergic immune responses. Curr Opin Immunol 2011; 23: 789-793.
150. Simons FE,. Anaphylaxis pathogenesis and treatment. Allergy 2011; 66 (Suppl 95): 31-34.
151. Sullivan BM, Liang HE, Bando JK, Wu D, Cheng LE, McKerrow JK, et al. Genetic analysis of basophil function in vivo. Nat Immunol 2011; 12: 527-535.
152. Karasuyama H, Wada T, Yoshikawa S, Obata K,. Emerging roles of basophils in protective immunity against parasites. Trends Immunol 2011; 32: 125-130.
153. Peavy RD, Metcalfe DD,. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 310-315.
154. Jensen-Jarolim E, Mechtcheriakova D, Pali-Schoell I,. The targets of IgE: allergen-associated and tumor-associated molecular patterns. In:, Penichet ML, Jensen-Jarolim E, editors. Cancer and IgE, Introducing the Concept of AllergoOncology. Cham, Switzerland: Springer Science+Business Media, 2010: 231-254.
155. Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, et al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcvarepsilonRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy 2011; 41: 1400-1413.
156. Jensen-Jarolim E, Singer J,. Why could passive immunoglobulin E antibody therapy be safe in clinical oncology? Clin Exp Allergy 2011; 41: 1337-1340.
157. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML,. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009; 112: 185-191.
158. Nel I, Baba HA, Ertle J, Weber F, Sitek B, Eisenacher M, et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 2013; 6: 420-428.
159. Williams SC,. Circulating tumor cells. Proc Natl Acad Sci USA 2013; 110: 4861.
160. Gould HJ, Mackay GA, Karagiannis SN, O'Toole CM, Marsh PJ, Daniel BE, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999; 29: 3527-3537. (Pubitemid 29527800)
161. Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ,. Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 1998; 10: 133-142. (Pubitemid 128736309)
162. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP,. Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 1998; 8: 517-529. (Pubitemid 28196805)
163. Fung-Leung WP, De Sousa-Hitzler J, Ishaque A, Zhou L, Pang J, Ngo K, et al. Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions. J Exp Med 1996; 183: 49-56. (Pubitemid 26028744)
164. Dombrowicz D, Brini AT, Flamand V, Hicks E, Snouwaert JN, Kinet JP, et al. Anaphylaxis mediated through a humanized high affinity IgE receptor. J Immunol 1996; 157: 1645-1651. (Pubitemid 126449106)
165. Dombrowicz D, Nutten S, Desreumaux P, Neut C, Torpier G, Peeters M, et al. Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. J Exp Med 2001; 193: 25-34. (Pubitemid 32060695)
166. Platzer B, Dehlink E, Turley SJ, Fiebiger E,. How to connect an IgE-driven response with CTL activity? Cancer Immunol Immunother 2012; 61: 1521-1525.
167. Daniels TR, Martinez-Maza O, Penichet ML,. Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother 2012; 61: 1535-1546.
168. Brazis P, De Mora F, Ferrer L, Puigdemont A,. IgE enhances Fc epsilon RI expression and IgE-dependent TNF-alpha release from canine skin mast cells. Vet Immunol Immunopathol 2002; 85: 205-212. (Pubitemid 34275433)
169. Bonkobara M, Miyake F, Yagihara H, Yamada O, Azakami D, Washizu T, et al. Canine epidermal langerhans cells express alpha and gamma but not beta chains of high-affinity IgE receptor. Vet Res Commun 2005; 29: 499-505. (Pubitemid 41548473)
170. Portier D, Richet C,. De l'action anaphylactique de certains venins. Comptes rendus de la Société de biologie 1902; 54: 170-172.
171. Ermel RW, Kock M, Griffey SM, Reinhart GA, Frick OL,. The atopic dog: a model for food allergy. Lab Anim Sci 1997; 47: 40-49.
172. Helm RM, Ermel RW, Frick OL,. Nonmurine animal models of food allergy. Environ Health Perspect 2003; 111: 239-244. (Pubitemid 36305324)
173. Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol 2012; 50: 200-209.
174. Kucharewicz I, Bodzenta-Lukaszyk A, Buczko W,. Experimental asthma in rats. Pharmacol Rep 2008; 60: 783-788.
175. Pauluhn J, Mohr U,. Experimental approaches to evaluate respiratory allergy in animal models. Exp Toxicol Pathol 2005; 56: 203-234. (Pubitemid 40312747)
176. Rashid A, Sadroddiny E, Ye HT, Vratimos A, Sabban S, Carey E, et al. Review: diagnostic and therapeutic applications of rat basophilic leukemia cells. Mol Immunol 2012; 52: 224-228.
177. Rowell JL, McCarthy DO, Alvarez CE,. Dog models of naturally occurring cancer. Trends Mol Med 2011; 17: 380-388.
178. Casal M, Haskins M,. Large animal models and gene therapy. Eur J Hum Genet 2006; 14: 266-272.
179. Perez Alenza MD, Pena L, del Castillo N, Nieto AI,. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract 2000; 41: 287-291.
180. Concannon PW,. Reproductive cycles of the domestic bitch. Anim Reprod Sci 2011; 124: 200-210.
181. Yang WY, Liu CH, Chang CJ, Lee CC, Chang KJ, Lin CT,. Proliferative activity, apoptosis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours. J Comp Pathol 2006; 134: 70-79.
182. Kumaraguruparan R, Prathiba D, Nagini S,. Of humans and canines: immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours. Res Vet Sci 2006; 81: 218-224. (Pubitemid 44191832)
183. Rutteman GR,. Contraceptive steroids and the mammary gland: is there a hazard?-Insights from animal studies. Breast Cancer Res Treat 1992; 23: 29-41.
184. van Garderen E, Schalken JA,. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol Cell Endocrinol 2002; 197: 153-165. (Pubitemid 35304789)
185. Mol JA, van Garderen E, Rutteman GR, Rijnberk A,. New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996; 57: 67-71.
186. Chlebowski RT, Anderson GL,. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012; 104: 517-527.
187. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013; 105: 526-535.
188. Schairer C, Brinton LA,. The effect of estrogen plus progestin hormone therapy on breast cancer mortality: still unresolved. J Natl Cancer Inst 2013; 105: 513-514.
189. Gama A, Gartner F, Alves A, Schmitt F,. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Res Vet Sci 2009; 87: 432-437.
190. Ahern TE, Bird RC, Bird AE, Wolfe LG,. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res 1996; 57: 693-696. (Pubitemid 126613626)
191. Dutra AP, Granja NV, Schmitt FC, Cassali GD,. c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res 2004; 37: 1673-1681. (Pubitemid 39549610)
192. Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L,. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010; 28: 1201-1208.